The FAK Inhibitor Defactinib Augments the Anti-Tumor Efficacy of the RAF/MEK Inhibitor Avutometinib for Patients with KRAS Mutant Cancers
- Scientific rationale leading to approval for patients with KRAS mutant low-grade serous ovarian cancer (LGSOC)
- Preclinical rationale and clinical update for patients with KRAS mutant PDAC and NSCLC
- Implications for FAK inhibitor combinations with the new generation of KRAS inhibitors